Pharsight

Bludigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11845867 PROVEPHARM SAS Process for the preparation of indigotindisulfonate sodium (indigo carmine)
Nov, 2036

(12 years from now)

US10927258 PROVEPHARM SAS Process for the preparation of Indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(13 years from now)

US11499050 PROVEPHARM SAS Process for the preparation of indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(13 years from now)

Bludigo is owned by Provepharm Sas.

Bludigo contains Indigotindisulfonate Sodium.

Bludigo has a total of 3 drug patents out of which 0 drug patents have expired.

Bludigo was authorised for market use on 08 July, 2022.

Bludigo is available in solution;intravenous dosage forms.

Drug patent challenges can be filed against Bludigo from 08 July, 2026.

The generics of Bludigo are possible to be released after 23 December, 2037.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 08, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: 08 July, 2026

Market Authorisation Date: 08 July, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BLUDIGO family patents

Family Patents